Recap: Stryker Q3 Earnings

Shares of Stryker SYK decreased 1.75% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 12.04% year over year to $2.14, which beat the estimate of $1.40.

Revenue of $3,737,000,000 higher by 4.18% year over year, which beat the estimate of $3,400,000,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Oct 29, 2020

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.stryker.com%2F&eventid=2402195&sessionid=1&key=6F956BA4E0187C3C1508F36D24099627&regTag=&sourcepage=register

Recent Stock Performance

52-week high: $227.39

Company's 52-week low was at $124.54

Price action over last quarter: Up 5.79%

Company Overview

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Slightly more than a quarter of Stryker's total revenue currently comes from outside the United States.